# NCT01622621 (NCT01622621)

> Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: high-risk early-stage NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01622621
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Mayo Clinic
- Conditions: Lung Neoplasms
- Interventions: Sublobar Resection; Stereotactic Body Radiotherapy (SBRT)
- Enrollment: 20
- Primary outcome: Number of patients alive at 2 years (Overall Survival [OS])

## Indexed commentary on NCT01622621 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct01622621